Helix BioPharma Statistics
Total Valuation
Helix BioPharma has a market cap or net worth of 118.05 million. The enterprise value is 117.94 million.
| Market Cap | 118.05M |
| Enterprise Value | 117.94M |
Important Dates
The next estimated earnings date is Friday, March 13, 2026.
| Earnings Date | Mar 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 76.38M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +35.46% |
| Shares Change (QoQ) | +7.02% |
| Owned by Insiders (%) | 6.58% |
| Owned by Institutions (%) | n/a |
| Float | 50.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 10.30 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -33.89 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -39.41 |
Financial Position
The company has a current ratio of 0.23, with a Debt / Equity ratio of 0.02.
| Current Ratio | 0.23 |
| Quick Ratio | 0.18 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.08 |
| Interest Coverage | -236.54 |
Financial Efficiency
Return on equity (ROE) is -66.34% and return on invested capital (ROIC) is -39.28%.
| Return on Equity (ROE) | -66.34% |
| Return on Assets (ROA) | -30.36% |
| Return on Invested Capital (ROIC) | -39.28% |
| Return on Capital Employed (ROCE) | -29.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -497,163 |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +89.22% in the last 52 weeks. The beta is -0.69, so Helix BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.69 |
| 52-Week Price Change | +89.22% |
| 50-Day Moving Average | 1.65 |
| 200-Day Moving Average | 2.64 |
| Relative Strength Index (RSI) | 67.57 |
| Average Volume (20 Days) | 719 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.38M |
| Pretax Income | -3.48M |
| Net Income | -3.48M |
| EBITDA | -3.37M |
| EBIT | -3.38M |
| Earnings Per Share (EPS) | -0.06 |
Balance Sheet
The company has 355,364 in cash and 251,895 in debt, with a net cash position of 103,469.
| Cash & Cash Equivalents | 355,364 |
| Total Debt | 251,895 |
| Net Cash | 103,469 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 11.46M |
| Book Value Per Share | 0.15 |
| Working Capital | -1.66M |
Cash Flow
In the last 12 months, operating cash flow was -2.99 million and capital expenditures -1,427, giving a free cash flow of -2.99 million.
| Operating Cash Flow | -2.99M |
| Capital Expenditures | -1,427 |
| Free Cash Flow | -2.99M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Helix BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -35.46% |
| Shareholder Yield | -35.46% |
| Earnings Yield | -2.95% |
| FCF Yield | -2.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 16, 2024. It was a reverse split with a ratio of 0.2.
| Last Split Date | Aug 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |